Alnylam Pharma (ALNY) Tops Q1 EPS by 92c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $224.03 -1.43%
Revenue Growth %: +14.5%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +14.5%
Financial Fact:
Other (expense) income: 229K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($0.01), $0.92 better than the analyst estimate of ($0.93). Revenue for the quarter came in at $594.19 million versus the consensus estimate of $588.75 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Lockheed Martin wins $114.6M F-35 navigation system contract
- Northrop Grumman wins $43.8M Navy contract for Trident II facility
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
